HGS Execs Hid Lupus Drug's Suicide Link: Suit

Law360, New York (December 22, 2011, 6:12 PM EST) -- A Human Genome Sciences Inc. shareholder lodged a derivative complaint Wednesday against the biotech company's CEO and several other officers and directors, alleging they hid from investors the fact that lupus drug Benlysta caused an elevated rate of suicide among users.

In a complaint filed in Maryland federal court, plaintiff Edward L. Forgione Jr. alleges Human Genome CEO H. Thomas Watkins and the rest of the company's management broke their fiduciary duties to shareholders and wasted corporate assets by failing to disclose disturbing side effects found...
To view the full article, register now.




Case Information

Case Title

Forgione v. Watkins et al

Case Number




Nature of Suit

Stockholders Suits


Roger W Titus

Date Filed

December 20, 2011

Law Firms


Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.